Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
SRRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.76 - $46.98
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.81M
Market Cap
$3.02B
Enterprise Value$3.76B
Total Cash (Recent Filing)$295.01M
Total Debt (Recent Filing)$61.53M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Nov 17, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding96,127,266
10 Day Avg. Volume1,721,420
30 Day Avg. Volume1,809,795
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.63K
Enterprise Value/Ebitda-11.79
Forecast
1Y Price Target
$49.20Price Target Upside55.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Commercial ReadinessScholar Rock confirmed that commercial supply of apitegromab has already been manufactured, with more than 600 patient-years of clinical safety experience accumulated using product made at the same sites.
Regulatory ProgressManagement indicates the clinical review of apitegromab's BLA is going well and remains aimed at a broad SMA label.
Bears Say
Manufacturing ConcernsCMC inspections have identified insufficiencies at two CDMOs (one being Catalent).
Regulatory ChallengesThere is a potential delay in the PDUFA decision due to procedural observations from a recent FDA site inspection, which could impact the approval timeline.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $6.76 and its highest was $46.98 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $3.02B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Nov 17, 2025 which is in 68 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Aug 06, 2025. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.665 by -$0.315.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.83.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 96,127,266 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.665. Following the earnings report the stock price went down -6.382%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in SRRK
Scholar Rock Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.20 (55.79% Upside)
$49.20 (55.79% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
293.27%
12-Months-Change
Fundamentals
Return on Equity
-172.08%
Trailing 12-Months
Asset Growth
49.89%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK Company Deck
SRRK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive outlook with significant regulatory and commercial progress for apitegromab, supported by strong financials and positive clinical trial results. However, there are challenges due to FDA observations at CDMO sites. While these issues pose potential risks, the company's preparedness and strategic initiatives provide confidence in overcoming these hurdles.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$49.20
▲(55.79% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
23.50% Insiders
31.40% Mutual Funds
0.07% Other Institutional Investors
33.98% Public Companies and
Individual Investors